[go: up one dir, main page]

WO1999035495A3 - Identification of substances that modify cellular secretory function - Google Patents

Identification of substances that modify cellular secretory function Download PDF

Info

Publication number
WO1999035495A3
WO1999035495A3 PCT/US1999/000551 US9900551W WO9935495A3 WO 1999035495 A3 WO1999035495 A3 WO 1999035495A3 US 9900551 W US9900551 W US 9900551W WO 9935495 A3 WO9935495 A3 WO 9935495A3
Authority
WO
WIPO (PCT)
Prior art keywords
substances
identification
secretory function
cellular secretory
modify cellular
Prior art date
Application number
PCT/US1999/000551
Other languages
French (fr)
Other versions
WO1999035495A2 (en
Inventor
Anice E Thigpen
Christian Quaade
Samuel A Clark
Original Assignee
Betagene Inc
Anice E Thigpen
Christian Quaade
Samuel A Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagene Inc, Anice E Thigpen, Christian Quaade, Samuel A Clark filed Critical Betagene Inc
Priority to CA 2318379 priority Critical patent/CA2318379A1/en
Priority to AU21121/99A priority patent/AU2112199A/en
Priority to EP99901421A priority patent/EP1047938A2/en
Publication of WO1999035495A2 publication Critical patent/WO1999035495A2/en
Publication of WO1999035495A3 publication Critical patent/WO1999035495A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/74—Alginate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides methods of screening for modulators of secretory function. In particular, the present invention describes immortalized neuroendocrine secretory cells to screen for novel substances that may be used to regulate secretory function in vitro and in vivo.
PCT/US1999/000551 1998-01-12 1999-01-11 Identification of substances that modify cellular secretory function WO1999035495A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA 2318379 CA2318379A1 (en) 1998-01-12 1999-01-11 Identification of substances that modify cellular secretory function
AU21121/99A AU2112199A (en) 1998-01-12 1999-01-11 Recombinant cell lines for drug screening
EP99901421A EP1047938A2 (en) 1998-01-12 1999-01-11 Identification of substances that modify cellular secretory function

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US7120998P 1998-01-12 1998-01-12
US7119398P 1998-01-12 1998-01-12
US7255698P 1998-01-12 1998-01-12
US60/071,209 1998-01-12
US60/071,193 1998-01-12
US60/072,556 1998-01-12
US8782198P 1998-06-03 1998-06-03
US8784898P 1998-06-03 1998-06-03
US60/087,821 1998-06-03
US60/087,848 1998-06-03

Publications (2)

Publication Number Publication Date
WO1999035495A2 WO1999035495A2 (en) 1999-07-15
WO1999035495A3 true WO1999035495A3 (en) 1999-11-25

Family

ID=27535873

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/000631 WO1999035255A2 (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines
PCT/US1999/000633 WO1999035242A1 (en) 1998-01-12 1999-01-11 Media for neuroendocrine cells
PCT/US1999/000551 WO1999035495A2 (en) 1998-01-12 1999-01-11 Identification of substances that modify cellular secretory function

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US1999/000631 WO1999035255A2 (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines
PCT/US1999/000633 WO1999035242A1 (en) 1998-01-12 1999-01-11 Media for neuroendocrine cells

Country Status (4)

Country Link
EP (2) EP1047938A2 (en)
AU (3) AU2112199A (en)
CA (2) CA2318379A1 (en)
WO (3) WO1999035255A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068136A1 (en) * 2000-03-17 2001-09-20 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
US7501231B2 (en) 2001-03-23 2009-03-10 University Of Ottawa Methods and compositions for cryopreservation of dissociated primary animal cells
US7166463B2 (en) 2001-11-16 2007-01-23 The Regents Of The University Of Colorado Nucleic acids encoding modified olfactory cyclic nucleotide gated ion channels
EP1893159B1 (en) 2005-06-17 2015-09-30 Vital Health Sciences Pty Ltd. A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents
DE602005017628D1 (en) 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusion polypeptides of glp-1 (glucagon-like peptide-1) with increased peptidase resistance
ES2629304T3 (en) 2006-01-04 2017-08-08 Baxalta Incorporated Cell culture medium without oligopeptides
ATE444741T1 (en) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Spherical microcapsules containing GLP-1 peptides, their production and their use
KR101495549B1 (en) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 Production of glycoproteins
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20100173409A1 (en) 2007-05-01 2010-07-08 Vitrolife Sweden Ab Culture media for developmental cells containing elevated concentrations of lipoic acid
JP5385280B2 (en) * 2007-09-11 2014-01-08 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of octreotide as a therapeutic agent
EP2163243A1 (en) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
CN104059955A (en) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 Production Of Proteins In Glutamine-free Cell Culture Media
EP2531047B1 (en) 2010-02-05 2024-11-13 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
KR20120115991A (en) * 2010-02-05 2012-10-19 포스파제닉스 리미티드 Carrier composition
WO2011120084A1 (en) 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
PT2678415T (en) * 2011-02-22 2019-07-19 Promethera Biosciences Sa Fill system for providing uniform concentrations and volumes and methods thereof
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US8945876B2 (en) 2011-11-23 2015-02-03 University Of Hawaii Auto-processing domains for polypeptide expression
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
WO2015066631A2 (en) * 2013-11-01 2015-05-07 University Of Notre Dame Du Lac Cell culture medium and bioprocess optimization
ES2716674T3 (en) 2013-11-22 2019-06-14 Centre Nat Rech Scient Frozen cell ready for testing and method to minimize variability in the performance of the same
US10918110B2 (en) 2015-07-08 2021-02-16 Corning Incorporated Antimicrobial phase-separating glass and glass ceramic articles and laminates
TW202440903A (en) * 2015-08-04 2024-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
JP7198754B2 (en) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド Method
KR102569522B1 (en) * 2017-11-24 2023-08-24 주식회사 차바이오랩 Composition for cryopreservation of cell and method for cryopreservation of cell using the same
WO2020206187A1 (en) * 2019-04-02 2020-10-08 Centagen, Inc Engineered system of stem cell rejuvenation to treat aging and disease
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN114868736B (en) * 2022-03-08 2022-12-09 四川中科奥格生物科技有限公司 Islet cell stabilizing solution and preparation method and application thereof
CN114561337B (en) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 Monoclonal enhancement culture medium and method for improving clone formation rate of HepG2 cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021979A1 (en) * 1991-06-03 1992-12-10 Board Of Regents, The University Of Texas System Methods and compositions relating to genetically engineered cells that produce insulin in response to glucose
US5180662A (en) * 1988-01-05 1993-01-19 The United States Of America As Represented By The Department Of Health And Human Services Cytotoxic T lymphocyte activation assay
WO1996011278A1 (en) * 1994-10-10 1996-04-18 Association Pour Le Developpement De L'immunologie Moleculaire-Adim Immortalized lines of endothelial brain cells and therapeutical applications thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650045B2 (en) * 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
WO1993002183A1 (en) * 1991-07-18 1993-02-04 Fuji Yakuhin Kogyo Kabushiki Kaisha Serum-free tissue culture medium containing tissue inhibitor of metalloproteinase and method for cell growth
GB9125052D0 (en) * 1991-11-26 1992-01-22 Isis Innovation Culture of bone cells
CA2246431A1 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180662A (en) * 1988-01-05 1993-01-19 The United States Of America As Represented By The Department Of Health And Human Services Cytotoxic T lymphocyte activation assay
WO1992021979A1 (en) * 1991-06-03 1992-12-10 Board Of Regents, The University Of Texas System Methods and compositions relating to genetically engineered cells that produce insulin in response to glucose
WO1996011278A1 (en) * 1994-10-10 1996-04-18 Association Pour Le Developpement De L'immunologie Moleculaire-Adim Immortalized lines of endothelial brain cells and therapeutical applications thereof

Also Published As

Publication number Publication date
EP1047938A2 (en) 2000-11-02
WO1999035242A9 (en) 1999-09-30
WO1999035255A2 (en) 1999-07-15
WO1999035255A8 (en) 1999-09-10
WO1999035255A3 (en) 1999-10-28
WO1999035255A9 (en) 2001-05-31
AU2113199A (en) 1999-07-26
AU2112199A (en) 1999-07-26
WO1999035495A2 (en) 1999-07-15
WO1999035242A1 (en) 1999-07-15
CA2318376A1 (en) 1999-07-15
CA2318379A1 (en) 1999-07-15
AU2455199A (en) 1999-07-26
EP1045898A2 (en) 2000-10-25

Similar Documents

Publication Publication Date Title
WO1999035495A3 (en) Identification of substances that modify cellular secretory function
NZ513598A (en) Immortalized cell lines and methods of making the same
IL141308A0 (en) Methods, instruments and materials for chondrocyte cell transplantation
HUP0105331A3 (en) Novel carbonyl reductase, gene thereof and method of using the same
WO1999055844A3 (en) Methods for modulating differentiation
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
GR3032605T3 (en) Sugar-modified cytostatics
WO2001034824A3 (en) Methods and compositions comprising renilla gfp
WO1999050459A3 (en) High throughput in vitro screening assays for transcription modulators
AU2001280673A1 (en) High-throughput methods for generating and screening compounds that affect cell viability
AU4423799A (en) Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
WO2002066954A3 (en) Pdz domain interactions and lipid rafts
WO2000066731A3 (en) Recombinant laminin 5
AU5875799A (en) Mip-1alpha isoform ld78beta and uses thereof
WO2001064837A3 (en) β NETRIN AND USES THEREOF
AU5545399A (en) High throughput in vitro screening assay for modulators of nucleic acid helicases
AU2002331366A1 (en) Dendritic cells and the uses thereof in screening cellular targets and potential drugs
WO2004075839A3 (en) Methods and compositions for modulating apoptosis
AU2003265902A1 (en) Electrochemical analytical apparatus and method of using the same
AU2342899A (en) Method of screening for neuropharmaceuticals using the (drosophila) gene (volado) and its mutants
AU1771799A (en) Acetyl-coa-carboxylase from candida albicans
AU2003273714A1 (en) Method for the electrochemical reduction of vat and sulphur dyes
AU2002325843A1 (en) Method for determining the interaction between keratinocytes and neurons
AU3612099A (en) Complex formed by a peptide and a major histocompatibility complex at the surface of phages
WO2004007702A3 (en) Modulators of chloride intracellular channel 1 protein signaling ____________________________________________________________

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2318379

Country of ref document: CA

Ref country code: CA

Ref document number: 2318379

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999901421

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999901421

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999901421

Country of ref document: EP